Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Oncology Institute (DFPH) over the last 5 years, with Q2 2025 value amounting to -$131000.0.

  • Oncology Institute's Tax Provisions changed N/A to -$131000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$131000.0, marking a year-over-year increase of 5828.03%. This contributed to the annual value of -$36000.0 for FY2023, which is 8518.52% up from last year.
  • According to the latest figures from Q2 2025, Oncology Institute's Tax Provisions is -$131000.0.
  • Over the past 5 years, Oncology Institute's Tax Provisions peaked at $799000.0 during Q3 2021, and registered a low of -$2.5 million during Q4 2021.
  • For the 4-year period, Oncology Institute's Tax Provisions averaged around -$83153.8, with its median value being $44000.0 (2023).
  • Over the last 5 years, Oncology Institute's Tax Provisions had its largest YoY gain of 625488.75% in 2021, and its largest YoY loss of 38815.9% in 2021.
  • Oncology Institute's Tax Provisions (Quarter) stood at -$2.5 million in 2021, then skyrocketed by 85.13% to -$367000.0 in 2022, then grew by 14.44% to -$314000.0 in 2023, then surged by 58.28% to -$131000.0 in 2025.
  • Its Tax Provisions was -$131000.0 in Q2 2025, compared to -$314000.0 in Q4 2023 and $135000.0 in Q3 2023.